Johnson & Johnson (JNJ)
16 Feb 2018
The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy.
Feb 14 The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy.
Feb 14 The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada treatment for use with prostate cancer patients whose cancer has not spread but continues to grow despite hormone therapy.
Drugmaker AbbVie Inc significantly boosted its 2018 earnings forecast on Friday with help from U.S. tax reform and said it hopes to accelerate dividend growth and share buybacks, sending its stock soaring to an all-time high.
A New Jersey state court judge on Monday delayed the start of a trial by a man who said he developed mesothelioma from being exposed to Johnson & Johnson's talc products after reversing a previous ruling that had barred a defense expert from testifying.
NEW YORK U.S. stocks advanced on Tuesday, as strong results from Netflix helped lift the S&P and Nasdaq Composite, but the Dow Industrials were hemmed in by declines in Johnson & Johnson and Procter & Gamble. | Video
Jan 23 The following bids, mergers, acquisitions and disposals were reported by 2030 GMT on Tuesday:
* Dow down 0.07 pct, S&P 500 up 0.15 pct, Nasdaq up 0.56 pct (Updates to mid-afternoon, changes byline)
A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug.
NEW YORK New York City on Tuesday sued eight companies that make or distribute prescription opioids, blaming them for fuelling a deadly epidemic afflicting the most populous U.S. city.
|General Electric Company (GE.N)||$15.05||+0.20|
|Procter & Gamble Co (PG.N)||$82.60||+0.19|
|Pfizer Inc. (PFE.N)||$36.26||+0.55|
|Novartis AG (NOVN.S)||CHF80.80||+1.18|
|Merck & Co., Inc. (MRK.N)||$56.29||+0.30|
|Baxter International Inc (BAX.N)||$66.33||-0.11|
|Stryker Corporation (SYK.N)||$159.87||+1.33|
|Boston Scientific Corporation (BSX.N)||$27.20||+0.11|
|Zimmer Biomet Holdings Inc (ZBH.N)||$120.48||+0.69|